OpenAI buys Orchestra Bio to bring drug-development agents into its Rosalind life sciences unit
The four-year-old startup builds agents that track trial schedules and finances for pharmaceutical teams. Terms were not disclosed.
OpenAI said on Tuesday that it has acquired Orchestra Bio, a four-year-old startup that builds AI agents to help biotech and pharmaceutical teams manage drug-development programs. Terms were not disclosed. TechCrunch reports that the startup had raised about $20 million as of 2025 from backers including Andreessen Horowitz, Atria and 8VC. Orchestra's staff and technology will join OpenAI's Rosalind life sciences business, which includes the Rosalind model and the Rosalind Workbench tool for planning experiments and analyzing results. OpenAI says Moderna and Novo Nordisk are among Rosalind's customers. Orchestra's agents monitor studies, track finances and resolve clinical trial scheduling problems. OpenAI gives the example of a failed manufacturing batch that threatens to delay a trial: the software would work out which activities and timelines are affected and weigh possible responses, while people still make the final decision. OpenAI says bringing a new medicine to U.S. approval takes 10 to 15 years on average, partly because programs pass between departments and partners whose systems often do not connect. It has given no timeline for adding Orchestra's agents to its products. TechCrunch describes the deal as an example of major AI labs building software for large industries such as pharma, which puts them in competition with startups.